Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Ravulizumab, a novel long‐acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two randomised, open‐label, phase 3 trials in C5 inhibitor‐naïve (Study 301) and eculizumab‐experienced (Study 302) adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Peffault de Latour, Régis, Brodsky, Robert A., Ortiz, Stephan, Risitano, Antonio M., Jang, Jun H., Hillmen, Peter, Kulagin, Alexander D., Kulasekararaj, Austin G., Rottinghaus, Scott T., Aguzzi, Rasha, Gao, Xiang, Wells, Richard A., Szer, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Red cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687070/
https://www.ncbi.nlm.nih.gov/pubmed/32449174
http://dx.doi.org/10.1111/bjh.16711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687070/
https://www.ncbi.nlm.nih.gov/pubmed/32449174
http://dx.doi.org/10.1111/bjh.16711

Ejemplares similares